Zydus Cadila Files First Indian New Drug Application


Indian drug producer Zydus Cadila has filed its first investigational new drug application for a new compound to treat metabolic disorder, following completion of preclinical studies. The molecule, known as ZY H1, has been developed to treat dyslipidemia and lower the high blood glucose levels associated with diabetes.

The company claims that the compound may be free of the reported side effects of glitazones, fibrates and statins used to treat related conditions, notably including obesity. Nevertheless, development of the product is still at an early stage, and a significant time away from any approvals in major developed markets.